Related Experiment Videos
Cytokines as potential vaccine adjuvants
1Center for Experimental Pharmacology and Therapeutics, Harvard-M.I.T. Division of Health Sciences and Technology, Cambridge, Massachusetts 02142.
Biotherapy (Dordrecht, Netherlands)
|January 1, 1994
Summary
Cytokines show promise as vaccine adjuvants to boost immune response against infections. Strategies like antigen fusion or encapsulation are needed to improve efficacy and reduce side effects for human use.
Area of Science:
- Immunology
- Vaccinology
Background:
- Adjuvants are crucial for enhancing vaccine efficacy, particularly in vulnerable populations like the very young, elderly, and immunocompromised.
- Existing vaccines against hepatitis B and Streptococcus pneumoniae could benefit from improved adjuvant strategies.
Purpose of the Study:
- To explore the potential of cytokines as vaccine adjuvants for human use.
- To identify strategies for optimizing cytokine adjuvant delivery to maximize efficacy and minimize toxicity.
Main Methods:
- Review of studies using recombinant cytokines (e.g., interleukins, interferons, TNF, G-CSF) as vaccine adjuvants.
- Investigation of antigen-cytokine fusion and encapsulation in liposomes or microspheres for improved delivery.
Main Results:
- Recombinant cytokines demonstrate vaccine adjuvant activity.
- Antigen fusion and encapsulation strategies are necessary to optimize adjuvant effects and reduce systemic toxicity.
Conclusions:
- Cytokines hold significant promise as vaccine adjuvants, but further research is required.
- Optimizing pharmacokinetic profiles and side effect profiles of cytokine-based adjuvants is essential for clinical application.